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Abstract: There is plausible biological evidence as well as epidemiologic evidence to 
suggest coffee consumption may lower endometrial cancer risk. We evaluated the 
associations between self-reported total coffee, caffeinated coffee and decaffeinated  
coffee, and endometrial cancer risk using the Women’s Health Initiative Observational 
Study Research Materials obtained from the National Heart, Lung, and Blood Institute 
Biological Specimen and Data Repository Coordinating Center. Our primary analyses 
included 45,696 women and 427 incident endometrial cancer cases, diagnosed over a total of 
342,927 person-years of follow-up. We used Cox-proportional hazard models to evaluate 
coffee consumption and endometrial cancer risk. Overall, we did not find an association 
between coffee consumption and endometrial cancer risk. Compared to non-daily drinkers 
(none or <1 cup/day), the multivariable adjusted hazard ratios for women who drank  
≥4 cups/day were 0.86 (95% confidence interval (CI) 0.63, 1.18) for total coffee, 0.89  
(95% CI 0.63, 1.27) for caffeinated coffee, and 0.51 (95% CI 0.25, 1.03) for decaf coffee. 
In subgroup analyses by body mass index (BMI) there were no associations among  
normal-weight and overweight women for total coffee and caffeinated coffee. However 
among obese women, compared to the referent group (none or <1 cup/day), the hazard 
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ratios for women who drank ≥2 cups/day were: 0.72 (95% CI 0.50, 1.04) for total coffee 
and 0.66 (95% CI 0.45, 0.97) for caffeinated coffee. Hazard ratios for women who drank  
≥2 cups/day for decaffeinated coffee drinkers were 0.67 (0.43–1.06), 0.93 (0.55–1.58) and 
0.80 (0.49–1.30) for normal, overweight and obese women, respectively. Our study 
suggests that caffeinated coffee consumption may be associated with lower endometrial 
cancer risk among obese postmenopausal women, but the association with decaffeinated 
coffee remains unclear. 
Keywords: coffee; endometrial cancer; estrogen; insulin; body mass index 
 
1. Introduction 
Known risk factors for endometrial cancer, such as use of unopposed estrogen, obesity, early 
menarche, and late age at menopause, support a hormonal etiology [1–6]. In support of this etiology, 
decreased plasma sex hormone binding globulin (SHBG) levels and elevated estrogen levels are 
associated with increased endometrial cancer risk [7,8]. Further, increased insulin resistance, 
hyperinsulinemia, and diabetes may increase endometrial cancer risk [1,2,9]. Coffee and caffeine 
consumption have been associated with increased plasma sex hormone binding globulin (SHBG) 
levels, decreased free estradiol levels [10–13], and improved insulin sensitivity [14]. Thus, it is 
biologically plausible that coffee consumption may reduce endometrial cancer risk. Additionally, since 
obese post-menopausal women have higher circulating estrogen [6] and insulin levels [15] than thinner 
post-menopausal women, the effect of coffee in reducing endometrial cancer risk may be greatest 
among these women. Although the association between obesity and endometrial cancer risk has been 
established, evidence linking dietary factors and endometrial cancer risk are limited [16]. 
To date three prospective cohort studies have evaluated the association between coffee consumption 
and endometrial cancer risk [17–19]. The only prospective study to examine this relationship by body 
mass index (BMI) subgroups observed the greatest reduction in risk among obese women [17]. 
Additionally, to our knowledge, no prospective study has examined the independent associations 
between caffeinated and decaffeinated coffee and endometrial cancer risk. 
We utilized the Women’s Health Initiative (WHI) Observational Study (OS) Research Materials 
obtained from the National Heart, Lung, and Blood Institute (NHLBI) Biological Specimen and Data 
Repository Coordinating Center to prospectively examine the association between coffee and 
endometrial cancer risk. With a large study population and access to detailed information on coffee 
consumption, these data provided a unique opportunity for evaluating the independent associations of 
caffeinated coffee and decaffeinated coffee overall and by BMI status. 
2. Methods 
2.1. Study Population 
The WHI OS is a multi-center, ethnically diverse prospective cohort study that enrolled  
93,676 eligible women aged 50–79 years. Details regarding study design, participant enrollment and 
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eligibility have been previously described [20]. Briefly, post-menopausal women who were unwilling 
or ineligible to participate in the clinical trial arms of the WHI study, did not plan to move and/or  
had expected survival time of three or more years were eligible to participate in the study.  
Participants were recruited at 40 clinical centers throughout the US between 1 October 1993 and  
21 December 1998. We accessed publicly available data from the WHI OS with follow-up through  
12 September 2005. 
2.2. Exclusion Criteria 
From the 93,676 women at baseline, we excluded participants from analysis who reported having a 
previous cancer other than non-melanoma skin cancer (n = 5355), hysterectomy (n = 32,429) or  
both—previous cancer other than non-melanoma skin cancer and hysterectomy (n = 6720) at baseline. 
We additionally excluded participants for whom there was no information available on follow-up  
(n = 260) or coffee consumption (n = 1935). Our primary analyses included 45,696 participants who 
contributed a total of 342,927 total person-years of follow-up. The average follow-up among the 
45,696 participants was 7.5 years.  
2.3. Exposure Variables 
Data on coffee consumption were collected at baseline using a structured questionnaire. Participants 
were asked “Do you usually drink coffee each day?” Participants answering “Yes” further indicated 
separately the number of cups of caffeinated and decaffeinated coffee they drank each day: None,  
1 cup/day, 2–3 cups/day, 4–5 cups/day, ≥6 cups/day. We created three coffee consumption variables: 
cups of total coffee consumed per day (caffeinated and/or decaffeinated coffee combined), cups of 
caffeinated coffee each day and cups of decaffeinated coffee each day. Participants who did not drink 
coffee on a daily basis served as the referent category for all analyses. Women also reported coffee 
consumption on a similarly worded questionnaire administered at year 3 of follow-up. 
2.4. Case Determination 
Adjudication of endometrial cancer cases in the WHI has been described previously [21]. Briefly, 
endometrial cancer cases were initially self-reported through annual questionnaires or at clinic visits 
every three years. Cases were locally and centrally adjudicated by trained physicians. Among our 
study population, 452 incident endometrial cancer cases were adjudicated during follow-up, among 
which 427 cases had complete information on key covariates. 
2.5. Statistical Analysis 
Baseline characteristics of participants were compared by cups of total coffee, caffeinated coffee 
and decaffeinated coffee consumption categories using chi-square tests or ANOVA as applicable. All 
coffee variables were categorized as: none or <1 cup/day (referent category), 1 cup/day, 2–3 cups/day 
and ≥4 cups/day for the overall analyses, and none or <1 cup/day, 1 cup/day and ≥2 cups/day for 
subgroup analyses, due to small numbers. Cox proportional hazard (PH) regression models were used 
to estimate hazard ratios (HR) and 95% confidence intervals (95% CI) for total coffee, caffeinated 
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coffee, and decaffeinated coffee consumption. We considered as potential confounders factors associated 
with coffee consumption as well as known or suspected risk factors for endometrial cancer. Variables 
initially considered were: age (years; continuous), ethnicity (white, black and other), unopposed 
estrogen use (never, past, current), combined estrogen-progestin use (never, past, current), smoking 
(never, past, current), BMI (kg/m2; continuous), age at menarche (<12, 12–13, >13 years), age at 
menopause (years; continuous), parity (No full term pregnancy, 1–2 full term pregnancies, ≥3 full term 
pregnancies), tea consumption (0, 1, 2–3, ≥4 cups/day), diabetes status (never, ever), physical activity 
(metabolic equivalents (METs/week; continuous)), history of oral contraceptive use (never, ever), 
family history of endometrial cancer (yes, no, don’t know) and total daily energy intake (kcal; 
continuous). We created a parsimonious model using stepwise selection and likelihood ratio tests, and 
adjusted for age, ethnicity, unopposed estrogen use, combined estrogen-progestin use, smoking, and 
BMI. Given its strong association with coffee consumption, we separately adjusted for cigarette 
smoking by duration of regular smoking (never/<100 cigarettes during lifetime, ≤9 years, 10–29 years, 
≥30 years), and pack-years of smoking (0, 1–9, 10–39, ≥40), and similar results were obtained using 
each approach. In models assessing caffeinated coffee and decaffeinated coffee, types of coffee were 
mutually adjusted for each other. Simultaneously adjusting for all other considered variables did not 
change our findings. Follow-up time for each participant was accrued from enrollment to date of 
diagnosis of endometrial cancer, date of hysterectomy, death, or date of last follow-up contact, 
whichever came first. Women who had a diagnosis of any other cancer during follow-up were not 
censored and were considered to be at risk of endometrial cancer. The assumption of proportional 
hazards in the Cox PH models was tested by including an interaction term with time, for all beverage 
consumption variables individually. There was no significant evidence of violation of the PH 
assumption in all reported models. 
We conducted further sub-group analyses by BMI as reported at baseline (<25 kg/m2, 25–29.9 kg/m2, 
and ≥30 kg/m2) adjusted for age only and for variables reported in the parsimonious multivariable 
adjusted models, for all coffee variables. For the sub-group analyses we only report results from the 
parsimonious models, as age adjusted hazard ratios were not different. We additionally performed 
analyses restricted to participants that reported drinking exclusively caffeinated coffee or drinking 
decaffeinated coffee at baseline. In the overall analyses, we formally tested for interaction between 
BMI and coffee consumption by adding an interaction term to our multivariable regression models. 
We conducted sensitivity analyses restricting the study population to those participants who were 
concordant in reporting their coffee consumption category at baseline and year 3 of follow-up. For 
these analyses, individuals who developed endometrial cancer, or had a hysterectomy, or had a 
censoring event (death, date of last-follow up contact) prior to the year 3 time point were not included. 
Two-sided p values <0.05 were considered statistically significant, with no adjustment for multiple 
comparisons. All analyses were performed using SAS version 9.2 (Cary, NC). 
3. Results 
The majority of women (71.1%) reported drinking coffee (caffeinated or decaffeinated) on a daily 
basis at baseline. Of these daily coffee consumers, the proportion of women that drank caffeinated 
coffee only, decaffeinated coffee only, and both was 53.4%, 19.3%, and 27.3%, respectively. 
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Compared to non-daily drinkers, total coffee consumers were more likely to be white and current 
smokers, and less likely to be obese and non-smokers (Table 1). Similar patterns were seen for both 
caffeinated coffee only consumers and decaffeinated coffee only consumers (data not shown). Daily 
coffee consumers were also significantly less likely to have diabetes at baseline (Table 1), however 
this trend was only in caffeinated coffee consumers and not in decaffeinated coffee consumers (data 
not shown).  
Table 1. Characteristics of study participants at baseline according to coffee consumption 
in the Women’s Health Initiative Observational Study (n = 46,977). 
 Daily total coffee consumption 
 0 or <1 cup/day 1 cup/day 2–3 cups/day ≥4 cups/day 
Continuous Mean (SD) Mean (SD) Mean (SD) Mean (SD) 
Age (years)  62.7 (7.5) 64.0 (7.4) 63.3 (7.2) 62.9 (7.1) 
Physical exercise (MET/week) 14.6 (15.0) 13.7 (14.4) 14.5 (14.3) 14.3 (14.7) 
Age at menopause  50.3 (4.9) 50.3 (5.1) 50.3 (5.1) 50.0 (4.8) 
Body mass index  27.1 (6.1) 26.8 (5.6) 26.8 (5.4) 26.8 (5.3) 
Total daily energy intake (kcal) 1528 (677) 1501 (689) 1554 (650) 1642 (716) 
Categorical n † % n † % n † % n † % 
Ethnicity         
White 10,828 (80.1) 5347 (78.6) 16,737 (88.5) 7071 (93.2) 
Black 1413 (10.5) 608 (8.9) 754 (4.0) 141 (1.9) 
Other 1284 (9.5) 851 (12.5) 1428 (7.6) 374 (4.9) 
Body mass index          
Normal BMI (<25 kg/m2) 5986 (44.6) 3028 (44.9) 8183 (43.6) 3177 (42.1) 
Overweight (25–30 kg/m2) 4110 (30.6) 2186 (32.4) 6420 (34.2) 2711 (36.0) 
Obese (≥30 kg/m2) 3327 (24.8) 1533 (22.7) 4157 (22.2) 1651 (21.9) 
Age at menarche         
Early menarche (<12 years) 2822 (20.9) 1347 (19.8) 4044 (21.4) 1682 (22.2) 
Average (12–13 years) 7395 (57.7) 3746 (55.1) 10,578 (56.0) 4190 (55.4) 
Late menarche (>13 years) 3301 (24.4) 1710 (25.1) 4272 (22.6) 1694 (22.4) 
Number of full term births         
None 2044 (15.2) 881 (13.0) 2468 (13.1) 1014 (13.4) 
1–2 4891 (36.3) 2464 (36.3) 6586 (35.0) 2620 (34.7) 
3 or more 6541 (48.5) 3439 (50.7) 9782 (51.9) 3911 (51.8) 
Smoking status         
Never smoked 8243 (61.4) 3752 (55.7) 8656 (46.2) 2855 (37.1) 
Past smoker 4741 (35.3) 2698 (40.1) 8907 (47.6) 3664 (48.9) 
Current smoker 444 (3.3) 282 (4.2) 1157 (6.2) 981 (13.1) 
Oral contraceptive use         
Never 7859 (57.9) 4187 (61.3) 11,038 (58.2) 4430 (58.3) 
Ever 5712 (42.1) 2643 (38.7) 7935 (41.8) 3173 (41.7) 
Diabetes Status         
No 12,581 (94.8) 6457  (94.6) 18,128 (95.7) 7289 (95.9) 
Yes 705 (5.2) 370 (5.4) 824 (4.3) 310 (4.1) 
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Table 1. Cont. 
Categorical n † % n † % n † % n † % 
Combined estrogen-progestin 
use   
Never used 7917 (58.4) 3920 (57.4) 10,527 (55.5) 4385 (57.7)
Past user 1173 (8.7) 615 (9.0) 1657 (8.7) 653 (8.6)
Current user 4472 (33.0) 2290 (33.6) 6779 (35.8) 2562 (33.7)
Unopposed estrogen use ‡   
Never used 11,957 (88.1) 5956 (87.3) 16,652 (87.8) 6722 (88.5)
Past user 1242 (9.2) 680 (10.0) 1832 (9.7) 698 (9.2)
Current user 368 (2.7) 190 (2.8) 482 (2.5) 179 (2.4)
Family history of endometrial 
cancer ‡   
No 221 (1.6) 89 (1.3) 238 (1.3) 103 (1.4)
Yes 5670 (41.8) 2947 (43.2) 8274 (43.6) 3229 (42.5)
Don’t know 7680 (56.6) 3794 (55.5) 10,461 (55.1) 4271 (56.1)
† Numbers may not add to 46,977 because of missing values. Due to the large sample size p values for all 
variables were <0.0001, except for ‡ unopposed estrogen use (p = 0.19); and ‡ family history of endometrial 
cancer (p = 0.96). 
We observed no overall inverse associations for total coffee, and caffeinated coffee and a marginally 
statistically significant inverse association between decaffeinated coffee and endometrial cancer risk. 
Compared to non-drinkers, the multivariable adjusted hazard ratios (HR) and 95% confidence intervals 
(95% CI) for women who drank ≥4 cups were: 0.86 (95% CI: 0.63–1.18) for total coffee, 0.89  
(0.63–1.27) for caffeinated coffee only, and 0.51 (0.25–1.03) for decaffeinated coffee only (Table 2). 
In sub-group analyses by BMI category, there were no statistically significant associations among 
normal weight and overweight women for total coffee, or caffeinated coffee consumption with 
endometrial cancer risk (Table 3). For decaffeinated coffee consumption there was a marginally 
significant association among normal weight women who drank ≥2 cups of decaffeinated coffee  
each day (HR: 0.67 (95% CI: 0.43–1.06)). However, this association among normal weight women 
was less apparent when we limited our analysis to women who exclusively drank decaffeinated coffee 
only (n = 8834); HR: 0.88 (95% CI: 0.57–1.57). We did not find any association among overweight 
women who drank ≥2 cups of decaffeinated coffee each day (HR: 0.93 (0.55–1.58)). 
In obese women, there was a borderline-significant lower risk (HR 0.72 (95% CI 0.50–1.04)) 
among women who drank ≥2 cups of total coffee/day, compared to obese women who were non-daily 
drinkers (Table 3). This inverse association among obese women was stronger and was statistically 
significant among women who drank ≥2 cups of caffeinated coffee/day (HR: 0.66 (95% CI: 0.45–0.97)) 
but less pronounced among women who drank ≥2 cups of decaffeinated coffee/each day (HR: 0.80 
(95% CI: 0.49–1.30)) (Table 3). Restricting our analyses to obese women who exclusively drank either 
caffeinated coffee only (n = 7511) or decaffeinated drinkers only (n = 4649), strengthened the effect 
estimates for both caffeinated coffee (HR: 0.60 (95% CI: 0.39–0.93)) and decaffeinated coffee  
(HR: 0.70 (0.37–1.33)). The interactions between the three coffee variables and BMI were not 
statistically significant; with p values of 0.38, 0.30 and 0.51 for total coffee, caffeinated coffee and 
decaffeinated coffee, respectively. 
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Table 2. Multivariable adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) of 
total coffee, caffeinated coffee and decaffeinated coffee in relation to endometrial cancer in 
the Women’s Health Initiative Observational Study (N = 45,696). 
Beverage consumption 0 or <1 cup/day 1 cup/day 2–3 cups/day ≥4 cups/day p-val a (trend) b 
Total Coffee      
Incident cases 126 71 168 62  
Person-years 98,679 49,010 138,726 56,512  
Age adjusted HR 
(95%CI) † 
1.00 (ref) 
1.07  
(0.80–1.43) 
0.92  
(0.73–1.50) 
0.85  
(0.63–1.15) 
 
Multivariable adjusted 
HR (95% CI) ‡ 
1.00 (ref) 
1.12  
(0.84–1.50) 
0.91  
(0.72–1.16) 
0.86  
(0.63–1.18) 
0.41 (0.23) 
Caffeinated Coffee      
Incident cases 185 81 121 40  
Person-years 148,060 57,188 101,564 36,112  
Age adjusted HR 
(95% CI) † 
1.00 (ref) 
1.13  
(0.82–1.57) 
0.89  
(0.68–1.17) 
0.96  
(0.67–1.39) 
 
Multivariable adjusted 
HR (95% CI) ‡ 
1.00 (ref) 
1.15  
(0.86–1.45) 
0.93  
(0.73–1.17) 
0.89  
(0.63–1.27) 
0.57 (0.45) 
Decaffeinated Coffee      
Incident cases 299 68 52 8  
Person-years 234,645 51,397 45,428 11,454  
Age adjusted HR 
(95% CI) † 
1.00 (ref) 
1.01  
(0.78–1.32) 
0.88  
(0.65–1.18) 
0.54  
(0.27–1.09) 
 
Multivariable adjusted 
HR (95% CI) ‡ 
1.00 (ref) 
0.99  
(0.76–1.30) 
0.84  
(0.63–1.13) 
0.51  
(0.25–1.03) 
0.19 (0.07) 
† Age adjusted hazard ratios (452 cases); ‡ Multivariable adjusted hazard ratios from Cox-proportional hazard 
regression models: adjusted for age (continuous), ethnicity (white, black and other), unopposed estrogen use 
(never, past, current), progestin + estrogen use (never, past, current), smoking (never, past, current) and BMI 
(continuous). When we examined caffeinated coffee or decaffeinated coffee in relation to endometrial cancer 
risk, each beverage was mutually adjusted for each other; a Represents p-value from likelihood ratio test for 
categorical coffee variables; b Represents p-value from linear trend test across coffee categories. 
Table 3. Multivariable HRs and 95% CIs of total coffee, caffeinated coffee and 
decaffeinated coffee consumption in relation to endometrial cancer by body mass index 
status in the Women’s Health Initiative Observational Study (N = 45,696). 
Beverage consumption 0 or <1 cup/day 1 cup/day ≥2 cups/day p-val a (trend) b P-int c 
Total Coffee     0.38 
Normal-weight (BMI < 25 kg/m2)     
N = 20,039      
Incident cases 50 27 99   
Person-years 44,601 22,450 84,986   
HR (95% CI) ‡ 1.00 (ref) 1.03  
(0.64–1.64) 
1.02  
(0.72–1.45) 
0.99 (0.90)  
Nutrients 2011, 3  
 
 
944
Table 3. Cont. 
Overweight (BMI 25 kg/m2–29.9 kg/m2)      
N = 15,159      
Incident cases 26 17 60   
Person-years 30,127 15,619 67,741   
HR (95% CI) ‡ 1.00 (ref) 1.21  
(0.66–2.32) 
1.01  
(0.63–1.60) 
0.79 (0.93)  
Obese (BMI ≥ 30 kg/m2)     
N = 10,498      
Incident cases 50 27 71   
Person-years 23,951 10,939 42,511   
HR (95% CI) ‡ 1.00 (ref) 1.20  
(0.70–1.79) 
0.72  
(0.50–1.04) 
0.08 (0.06)  
Caffeinated Coffee     0.30 
Normal-weight (BMI < 25 kg/m2)     
N = 20,039      
Incident cases 70 34 72   
Person-years 66,860 26,212 58,965   
HR (95% CI) ‡ 1.00 (ref) 1.23  
(0.81–1.87) 
1.17  
(0.83–1.64) 
0.53 (0.37)  
Overweight (BMI 25 kg/m2–29.9 kg/m2)     
N = 15,159      
Incident cases 44 16 43   
Person-years 46,985 18,717 47,785   
HR (95% CI) ‡ 1.00 (ref) 0.88  
(0.50–1.58) 
0.99  
(0.65–1.53) 
0.91 (0.99)  
Obese (BMI ≥ 30 kg/m2)     
N = 10,498      
Incident cases 71 31 46   
Person-years 34,215 12,259 30,927   
HR (95% CI) ‡ 1.00 (ref) 1.16  
(0.75–1.78) 
0.66  
(0.45–0.97) 
0.03 (0.05)  
Decaffeinated Coffee     0.51 
Normal-weight (BMI < 25 kg/m2)     
N = 20,039      
Incident cases 129 25 22   
Person-years 102,756 23,973 25,307   
HR (95% CI) ‡ 1.00 (ref) 0.77  
(0.50–1.18) 
0.67  
(0.43–1.06) 
0.15 (0.06)  
Overweight (BMI 25 kg/m2–29.9 kg/m2)     
N = 15,159      
Incident cases 68 17 18   
Person-years 76,691 16,583 20,212   
HR (95% CI) ‡ 1.00 (ref) 1.10  
(0.64–1.87) 
0.93  
(0.55–1.58) 
0.90 (0.86)  
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Table 3. Cont. 
Obese (BMI ≥ 30 kg/m2)     
N = 10,498      
Incident cases 102 26 20   
Person-years 55,198 10,840 11,362   
HR (95% CI) ‡ 1.00 (ref) 1.17  
(0.76–1.82) 
0.80  
(0.49–1.30) 
0.44 (0.63)  
‡ Multivariable adjusted hazard ratios from Cox-proportional hazard regression models: adjusted for age 
(continuous), ethnicity (white, black and other), unopposed estrogen use (never, past, current), combined 
estrogen-progestin use (never, past, current), and smoking (never, past, current). When we examined 
caffeinated coffee or decaffeinated coffee in relation to endometrial cancer risk, each beverage was mutually 
adjusted for each other; a Represents p-value from likelihood ratio test for categorical coffee variables;  
b Represents p-value from linear trend test across coffee categories; c Represents p-value for interaction. 
Adjustment for cigarette smoking by duration of smoking or pack-years of smoking separately 
while adjusting for variables included in the main models did not change our results. After adjusting 
for duration of smoking, the multivariable adjusted HRs and 95% CI among obese women who drank 
≥2 cups of caffeinated coffee and decaffeinated coffee were 0.65 (0.44–0.95) and 0.79 (0.49–1.29) 
respectively, compared to non-daily drinkers. Similarly, after adjusting for pack-years of smoking 
associations were 0.66 (0.45–0.97) and 0.78 (0.47–1.27) for caffeinated coffee and decaffeinated 
coffee, respectively. 
We observed similar results in analyses further restricted to women who reported drinking the same 
number of coffee cups/day category at both baseline and year 3 (n = 3898). However, the inverse 
association between ≥2 cups caffeinated coffee consumption and endometrial cancer risk among obese 
women was strengthened (HR: 0.40 (95% CI: 0.18–0.91)). 
We also examined the association between tea consumption and endometrial cancer risk, while 
adjusting for variables in the parsimonious models and coffee consumption. No statistically significant 
associations were observed overall (multivariable HR 1.10, 95% CI 0.61–1.97 for ≥4 cups/day vs.  
non-daily tea consumption) or within BMI categories (data not shown). 
4. Discussion 
In this large prospective cohort study of post-menopausal women, we found some evidence of an 
overall inverse association between decaffeinated coffee and endometrial cancer risk, and no such 
overall associations for total coffee, or caffeinated coffee. However, within the subgroup of obese 
women (baseline BMI ≥ 30 kg/m2), we observed a lower risk of endometrial cancer among obese 
women who drank ≥2 cups/day of coffee. Though these observations were based on a small number of 
cases, the results suggest that coffee consumption may lower endometrial cancer risk among obese 
women, who also have the highest absolute risk in comparison to thin women. 
Three other studies [17–19] have prospectively evaluated coffee consumption and endometrial 
cancer risk. The Swedish Mammography Cohort, the large study of predominantly post-menopausal 
women who primarily drank caffeinated coffee, reported an overall 25% lower risk in the highest 
category of coffee drinkers [17]. Additionally, they showed that the reduction in risk was strongest 
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among heavy women and not present in normal weight women. Our results are most consistent with 
this Swedish study as we too found an inverse association between caffeinated coffee consumption and 
endometrial cancer risk among obese women [17]. A second prospective study conducted in Japan 
reported a 62% overall lower risk among women with the highest coffee consumption [18]. The 
smallest prospective study in Norway did not show an inverse association between coffee intake and 
endometrial cancer risk [19]. However, the referent category in this study included women who drank 
≤2 cups of coffee per day and over 60% of the women were pre-menopausal at baseline. Furthermore, 
neither of the two studies from Japan or Norway evaluated risk by BMI strata. To our knowledge our 
study is the first to prospectively evaluate decaffeinated coffee and endometrial cancer risk. Our results 
were slightly suggestive of an inverse association, with heterogeneous results across BMI strata. Only 
two case-control studies have evaluated decaffeinated coffee and both showed null associations [22,23]. 
The unopposed estrogen hypothesis provides a compelling explanation for the etiology of most 
endometrial cancer [5]. It posits that estrogen exposure stimulates uncontrolled cell division in the 
endometrium, increasing the likelihood of deleterious mutations that may result in endometrial  
cancer [24]. Consistent with this hypothesis, studies indicate postmenopausal women with higher 
serum estrogens have an increased risk of endometrial cancer [7,8]. In addition, lower blood levels of 
SHBG are also associated with increased endometrial cancer risk [7,8], presumably because SHBG 
binds to estradiol, thereby reducing the levels of bio-available estrogen. Diabetes and hyperinsulinemia 
are also hypothesized to play a role in endometrial carcinogenesis [1,2,9]. Specifically, insulin may 
promote endometrial cancer development directly as a mitogen [25] or indirectly through its effects on 
estrogen availability [26,27]. Several biological mechanisms related to these two pathways could 
account for a possible inverse association between caffeinated coffee intake and endometrial cancer 
risk. In line with the well-established estrogen-mediated etiology of endometrial cancer, higher intake 
of caffeinated coffee or caffeine has been associated with increased blood levels of sex hormone 
binding globulin in postmenopausal women [10–13,28]. In postmenopausal women, caffeinated coffee 
intake has also been associated with blood markers of decreased insulin secretion and improved insulin 
sensitivity, including lower C-peptide levels [29], and higher adiponectin levels [30]. In a study by Wu 
and colleagues, the inverse association between caffeinated coffee consumption and plasma C-peptide 
levels was stronger in obese and overweight women than in normal-weight women [30]. This 
observation is consistent with our findings and those of Friberg and colleagues who showed that the 
reduction in risk through caffeinated coffee consumption was greatest among heavier women [17]. 
Coffee also has a number of different phytochemicals other than caffeine that could also play a role in 
endometrial cancer carcinogenesis. For example, chlorogenic acid has been suggested to also delay 
glucose absorption and improve insulin sensitivity [31–33]. Other constituents of coffee may act as 
antioxidants [34] or have anti-estrogenic properties [35,36] that could also have relevance to 
endometrial carcinogenesis, particularly in heavier women. 
We observed an overall association with decaffeinated coffee, although the pattern was not 
consistently observed across all body mass index categories. Decaffeinated coffee intake has been 
linked to decreased C-peptide levels in postmenopausal women [29]. Contrary to observations for 
caffeinated coffee intake, however, decaffeinated coffee intake has not been linked to elevated blood 
levels of adiponectin [30], elevated levels of SHBG [28], or lower levels of total estrogens [28]. A 
possible explanation for inverse association for decaffeinated coffee we observed is chance, as only a 
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small percentage of our population drank decaffeinated coffee daily. Alternatively, our findings  
for decaffeinated coffee may reflect confounding by unknown factors, as decaffeinated coffee  
drinkers may be a unique population. The results for decaffeinated coffee are unclear and additional 
large studies that are able to separate caffeinated and de-caffeinated coffee may shed further light on 
this issue. 
Major strengths of our study include its prospective design, detailed information on coffee 
consumption and potential covariates, and adjudication of endometrial cancer cases. Due to the 
prospective nature of the study and limited loss to follow up, the likelihood of recall bias and selection 
bias are minimal. Additionally, the large study population allowed us to examine the independent 
effects of caffeinated and decaffeinated coffee consumption. Our study is limited by its reliance on 
self-reported values for coffee consumption without specification of serving size per cup, which may 
have attenuated our results to towards the null. We additionally did not have information on other 
sources of caffeine, such as soft drinks and energy drinks, nor were data available on use of additives 
such as sugar, honey, and cream. Furthermore, we did not have access to DNA samples and were not 
able to evaluate potential gene-diet interactions. For example, polymorphisms of CYP1A2 gene are 
associated with differential metabolism of caffeine [37] and estrogen [38]. Examination of such  
gene-diet interactions in future studies may help to elucidate the underlying mechanisms associated 
with coffee consumption and endometrial cancer risk.  
5. Conclusions 
In conclusion, we extend evidence from previous publications in suggesting a lower risk of 
endometrial cancer among obese women for caffeinated coffee. Our results for decaffeinated coffee 
consumption and endometrial cancer risk were slightly suggestive of an inverse association; however 
we observed an inconsistent pattern in subgroups of women defined by body mass index. Furthermore, 
our study adds to an increasing body of evidence that suggests an inverse association between coffee 
consumption and several types of cancer including, bladder, breast, endometrial, hepatocellular, 
pancreatic and prostate cancer [39]. 
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